Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Fig. 2

Day 85 SGRQ responders by patient subgroup. The odds ratios for revefenacin versus placebo was statistically significant (p < 0.05) for the following subgroups: ITT, FEV1 30%–< 50% predicted and, 2011 GOLD category D. The subgroup, FEV1 < 30% predicted, has been excluded from the forest plot due to being out with the range of the x-axis scale. CI confidence intervals; CV cardiovascular; FEV1 forced expiratory volume in 1 s; GOLD Global Initiative for Chronic Obstructive Lung Disease; LABA long-acting ß agonist; ICS inhaled corticosteroids; ITT intention-to-treat; SGRQ St. George’s Respiratory Questionnaire

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us